|
Real-time Estimate
Cboe BZX
15:03:31 22/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.180 USD | +1.46% |
|
+3.59% | +159.94% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: MacroGenics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 983.2 | 412.5 | 596.7 | 204 | 101.8 | 262.4 | - | - |
| Change | - | -58.04% | 44.66% | -65.82% | -50.07% | 157.69% | - | - |
| Enterprise Value (EV) | 983.2 | 412.5 | 366.9 | 204 | 101.8 | 262.4 | 262.4 | 262.4 |
| Change | - | -58.04% | -11.05% | -44.41% | -50.07% | 157.69% | 0% | 0% |
| P/E | -4.76x | -3.44x | -64.1x | -3.04x | -1.36x | -2.64x | -2.51x | -2.01x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | 0.7x | -0x | -0.1x | -0.1x | -0.48x | -0.1x |
| Capitalization / Revenue | 12.7x | 2.71x | 10.2x | 1.36x | 0.68x | 2.43x | 2.9x | 2.91x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.43x | 2.9x | 2.91x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.84x | -2.01x | -1.57x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -3.12x | -1.89x | -2x |
| FCF Yield | -15.3% | -22% | -13.4% | -35.3% | -81.5% | -32% | -53% | -49.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.37 | -1.95 | -0.15 | -1.07 | -1.18 | -1.558 | -1.64 | -2.049 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 77.45 | 151.9 | 58.75 | 150 | 149.5 | 108.2 | 90.61 | 90.12 |
| EBITDA | -191.5 | -109.6 | -158.6 | - | - | - | - | - |
| EBIT 1 | -202.8 | -121.4 | -168.2 | -110.6 | -72.84 | -92.47 | -130.9 | -167.6 |
| Net income 1 | -202.1 | -119.8 | -9.058 | -66.97 | -74.62 | -88.7 | -138.1 | -180.5 |
| Net Debt | - | - | -229.8 | - | - | - | - | - |
| Reference price 2 | 16.050 | 6.710 | 9.620 | 3.250 | 1.610 | 4.120 | 4.120 | 4.120 |
| Nbr of stocks (in thousands) | 61,258 | 61,475 | 62,029 | 62,763 | 63,259 | 63,700 | - | - |
| Announcement Date | 24/02/22 | 15/03/23 | 07/03/24 | 20/03/25 | 09/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.64x | - | - | - | 262M | |
| 21.82x | 7.74x | 15.55x | 1.36% | 74.33B | |
| 32.35x | 9.35x | 29.12x | 0.04% | 62.26B | |
| 32.02x | 6.83x | 17.73x | -.--% | 27.72B | |
| -73.86x | 14.28x | -68.86x | -.--% | 26.42B | |
| -14.99x | 5.59x | -7.02x | -.--% | 24.62B | |
| 28.25x | 5.33x | 17.69x | -.--% | 20.72B | |
| 43.37x | 15.89x | 32.23x | 0.35% | 15.01B | |
| 17.67x | 5.26x | 12.29x | -.--% | 14.18B | |
| -14.6x | 3288.74x | -16.82x | -.--% | 13.48B | |
| Average | 6.94x | 373.22x | 3.54x | 0.19% | 27.9B | |
| Weighted average by Cap. | 12.52x | 167.26x | 8.13x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MGNX Stock
- Valuation MacroGenics, Inc.
Select your edition
All financial news and data tailored to specific country editions
